JP6403219B2 - ベータ−ラクタマーゼ阻害剤 - Google Patents

ベータ−ラクタマーゼ阻害剤 Download PDF

Info

Publication number
JP6403219B2
JP6403219B2 JP2015545855A JP2015545855A JP6403219B2 JP 6403219 B2 JP6403219 B2 JP 6403219B2 JP 2015545855 A JP2015545855 A JP 2015545855A JP 2015545855 A JP2015545855 A JP 2015545855A JP 6403219 B2 JP6403219 B2 JP 6403219B2
Authority
JP
Japan
Prior art keywords
optionally substituted
acid
alkyl
formula
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502973A (ja
JP2016502973A5 (enExample
Inventor
バーンズ，クリストファー，ジェイ．
デイグル，デニス
リウ，ビン
マクギャリー，ダニエル
シー． ペビアー，ダニエル
シー． ペビアー，ダニエル
イー．リー トラウト，ロバート
イー．リー トラウト，ロバート
Original Assignee
ベナトルクス ファーマシューティカルズ，インク．
ベナトルクス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベナトルクス ファーマシューティカルズ，インク．, ベナトルクス ファーマシューティカルズ，インク． filed Critical ベナトルクス ファーマシューティカルズ，インク．
Publication of JP2016502973A publication Critical patent/JP2016502973A/ja
Publication of JP2016502973A5 publication Critical patent/JP2016502973A5/ja
Application granted granted Critical
Publication of JP6403219B2 publication Critical patent/JP6403219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2015545855A 2012-12-07 2013-12-05 ベータ−ラクタマーゼ阻害剤 Active JP6403219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US61/734,900 2012-12-07
US201361783238P 2013-03-14 2013-03-14
US61/783,238 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018114967A Division JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016502973A JP2016502973A (ja) 2016-02-01
JP2016502973A5 JP2016502973A5 (enExample) 2016-12-01
JP6403219B2 true JP6403219B2 (ja) 2018-10-10

Family

ID=50884012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545855A Active JP6403219B2 (ja) 2012-12-07 2013-12-05 ベータ−ラクタマーゼ阻害剤
JP2018114967A Pending JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018114967A Pending JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Country Status (16)

Country Link
US (6) US9422314B2 (enExample)
EP (2) EP2928898B1 (enExample)
JP (2) JP6403219B2 (enExample)
KR (1) KR102147420B1 (enExample)
CN (1) CN105026407B (enExample)
AU (1) AU2013355110B2 (enExample)
BR (1) BR112015013123B1 (enExample)
CA (1) CA2893943C (enExample)
ES (1) ES2878118T3 (enExample)
HR (1) HRP20210879T1 (enExample)
IL (1) IL239212B (enExample)
PL (1) PL2928898T3 (enExample)
PT (1) PT2928898T (enExample)
RU (1) RU2654692C2 (enExample)
WO (1) WO2014089365A1 (enExample)
ZA (1) ZA201504200B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518991A (ja) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
JP2018184409A (ja) * 2012-12-07 2018-11-22 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2941246A4 (en) * 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
SMT201900611T1 (it) 2014-05-05 2020-01-14 Rempex Pharmaceuticals Inc Sintesi di sali boronati e usi degli stessi
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
MX2016016666A (es) * 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2761778T3 (es) * 2014-12-19 2020-05-21 Rempex Pharmaceuticals Inc Aparato y proceso de flujo continuo para la producción de derivados de ácido borónico
EP3240784A2 (en) * 2014-12-23 2017-11-08 BerGenBio ASA Inhibitors of akt kinase
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
DK3478693T3 (da) * 2016-06-30 2021-09-20 Qpex Biopharma Inc Boronsyrederivater og terapeutiske anvendelser deraf
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
IL268981B2 (en) 2017-03-06 2023-09-01 Venatorx Pharmaceuticals Inc Solid forms and combined preparations containing beta-lactamase inhibitor and uses thereof
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
EP3630782A4 (en) * 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
JP7480050B2 (ja) 2017-11-01 2024-05-09 メリンタ セラピューティクス インコーポレイテッド ボロン酸エステル誘導体の合成およびその使用
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN118638140A (zh) * 2018-04-27 2024-09-13 住友制药株式会社 氧代取代化合物
EP3802551A4 (en) * 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US20220054513A1 (en) * 2018-09-12 2022-02-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
JP2022529212A (ja) * 2019-04-02 2022-06-20 ベナトルクス ファーマシューティカルズ，インク． 経口送達されるベータ－ラクタマーゼ阻害剤の固体形態およびその使用
EP4049680A4 (en) 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
TW202128718A (zh) 2019-11-26 2021-08-01 美商維納拓爾斯製藥公司 青黴素結合蛋白抑制劑
KR20230104117A (ko) * 2020-08-20 2023-07-07 파에노 테라퓨틱스 씨오., 엘티디. 붕산계 화합물
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
BR112023017203A2 (pt) 2021-04-13 2023-11-07 Tuojie Biotech Shanghai Co Ltd Derivado de ácido bórico que age como inibidor de beta-lactamase
CN119384424A (zh) * 2022-02-18 2025-01-28 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
EP1212327B8 (en) 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2004256841A1 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
SI1756121T1 (sl) 2004-03-30 2012-03-30 Millennium Pharm Inc Sinteza estra borove kisline in kislinske spojine
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
CA2629570C (en) 2005-12-07 2012-11-27 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
AU2008321443A1 (en) 2007-11-13 2009-05-22 Novartis Ag Beta-lactamase inhibitors
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
AU2011373912B2 (en) 2011-07-26 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JP6211418B2 (ja) 2011-09-04 2017-10-11 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
HK1206261A1 (en) 2011-12-22 2016-01-08 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JP6018319B2 (ja) 2012-12-03 2016-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換トリアゾールボロン酸化合物
AU2013355110B2 (en) * 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2941246A4 (en) 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) * 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
ES2874579T3 (es) 2014-06-11 2021-11-05 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9949982B2 (en) 2014-09-04 2018-04-24 Shionogi & Co., Ltd. Preparation containing cephalosporin having a catechol moiety
ES2761778T3 (es) 2014-12-19 2020-05-21 Rempex Pharmaceuticals Inc Aparato y proceso de flujo continuo para la producción de derivados de ácido borónico
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
IL268981B2 (en) 2017-03-06 2023-09-01 Venatorx Pharmaceuticals Inc Solid forms and combined preparations containing beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018184409A (ja) * 2012-12-07 2018-11-22 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
JP2017518991A (ja) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Also Published As

Publication number Publication date
AU2013355110B2 (en) 2017-11-09
ZA201504200B (en) 2017-09-27
KR102147420B1 (ko) 2020-08-25
US20180194783A1 (en) 2018-07-12
JP2016502973A (ja) 2016-02-01
PL2928898T3 (pl) 2021-10-25
US9828391B2 (en) 2017-11-28
HRP20210879T1 (hr) 2021-08-20
PT2928898T (pt) 2021-07-05
HK1217334A1 (zh) 2017-01-06
EP2928898A1 (en) 2015-10-14
US20190225628A1 (en) 2019-07-25
EP2928898B1 (en) 2021-04-14
CN105026407B (zh) 2017-09-08
US20160326189A1 (en) 2016-11-10
AU2013355110A1 (en) 2015-07-02
US10214547B2 (en) 2019-02-26
BR112015013123B1 (pt) 2021-02-17
EP3922635A1 (en) 2021-12-15
IL239212A0 (en) 2015-07-30
CN105026407A (zh) 2015-11-04
US9422314B2 (en) 2016-08-23
EP2928898A4 (en) 2016-06-29
CA2893943C (en) 2021-03-02
US20140171390A1 (en) 2014-06-19
US8912169B2 (en) 2014-12-16
JP2018184409A (ja) 2018-11-22
ES2878118T3 (es) 2021-11-18
BR112015013123A2 (pt) 2017-07-11
US20150291630A1 (en) 2015-10-15
IL239212B (en) 2019-10-31
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
US10669290B2 (en) 2020-06-02
CA2893943A1 (en) 2014-06-12
RU2654692C2 (ru) 2018-05-22
US20250236632A1 (en) 2025-07-24
WO2014089365A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
JP6403219B2 (ja) ベータ−ラクタマーゼ阻害剤
US11414435B2 (en) Beta-lactamase inhibitors
HK1217334B (en) Beta-lactamase inhibitors
HK1217446B (zh) β-内酰胺酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180906

R150 Certificate of patent or registration of utility model

Ref document number: 6403219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250